Abbott, a leader in diabetes tech with one of the biggest lines of continuous glucose monitors, announced this week that it's ...

Abbott’s continuous glucose monitoring (CGM) device, the FreeStyle Libre, has been integrated with Glooko’s digital platform for diabetes management. The integration is available for individuals with ...

The system – which already has a breakthrough device designation from the FDA – will take the form of a small patch-like device similar to Abbott's FreeStyle Libre 3 device (pictured above ...

MANCHESTER, N.H., March 18, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, today announced that Abbott’s FreeStyle Libre 3 ...

The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

Investors feel optimistic about Abbott's robust strength in the EPD, Diabetes and Nutrition businesses. However, unfavorable forex impacts are concerning.

Abbott's FreeStyle Libre system and new Protality brand highlight its long-term growth potential in diabetes care and weight-loss treatment markets. With a 12-18 month price target of $145-$160 ...

“Abbott’s FreeStyle Libre technology, known for its user-friendly design and broad accessibility, complements our innovative system.” According to the Manchester, New Hampshire-based ...

We like that management has turned its attention to new sources of growth. In our view, Abbott's FreeStyle Libre blood glucose monitor is one of the most compelling innovations the firm has ever ...